rupiya.io
⠋Loading...
0%
❯ Analyzing price movements...
Strides Pharma Science Ltd is a Drug Manufacturers - Specialty & Generic company listed on NSE. The page combines exchange quotes, financial statements, shareholding, filings, and news so investors can review the business in one place.
Strides Pharma Science Ltd makes money through Domestic formulations, Exports and regulated markets, Specialty or institutional sales in Drug Manufacturers - Specialty & Generic. Revenue quality depends on demand growth, margin discipline, balance-sheet strength, and the company's ability to defend its position within Pharma.
Create a free account to view momentum, moving averages, and delivery signals.
Upgrade to view volatility, drawdown, factor, and risk metrics.
| Period | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | ₹1,196 Cr | ₹2,861 Cr | ₹2,755 Cr | ||||||||
| Expenses | ₹967 Cr | ₹2,486 Cr | ₹2,228 Cr | ||||||||
| Operating Profit | ₹229 Cr | ₹374 Cr | ₹527 Cr | ||||||||
| OPM % | 19.0% | 13.0% | 19.0% | ||||||||
| Other Income | ₹874 Cr | ₹63 Cr | ₹291 Cr | ||||||||
| Depreciation | ₹64 Cr | ₹131 Cr | ₹126 Cr | ||||||||
| Interest | ₹47 Cr | ₹168 Cr | ₹183 Cr | ||||||||
| Profit Before Tax | ₹992 Cr | ₹137 Cr | ₹509 Cr | ||||||||
| Tax | ₹992 Cr | ₹137 Cr | ₹509 Cr | ||||||||
| Net Profit | ₹844 Cr | ₹95 Cr | ₹446 Cr | ||||||||
| EPS (₹) | 141.8 | 12.2 | 44.7 | ||||||||
| Dividend Payout % | 76% | 41% | 10% |
Register free to see 8 more years.
| Quarter | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | ₹986 Cr | ₹930 Cr | ₹999 Cr | ₹1,006 Cr | ||||||||
| Expenses | ₹871 Cr | ₹796 Cr | ₹889 Cr | ₹876 Cr | ||||||||
| Operating Profit | ₹115 Cr | ₹134 Cr | ₹111 Cr | ₹129 Cr | ||||||||
| OPM % | 12.0% | 14.0% | 11.0% | 13.0% | ||||||||
| Depreciation | ₹61 Cr | ₹60 Cr | ₹60 Cr | ₹49 Cr | ||||||||
| Interest | ₹81 Cr | ₹76 Cr | ₹79 Cr | ₹70 Cr | ||||||||
| Net Profit | ₹-14 Cr | ₹-9 Cr | ₹-149 Cr | ₹54 Cr | ||||||||
| EPS (₹) | -1.1 | -0.8 | -14.5 | 5.4 |
Register free to see 8 more quarters.
| Period | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Liabilities | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Equity Capital | ₹60 Cr | ₹89 Cr | ₹89 Cr | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Reserves | ₹1,085 Cr | ₹2,569 Cr | ₹2,659 Cr | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Borrowings | ₹892 Cr | ₹3,542 Cr | ₹3,700 Cr | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Other Liabilities | ₹438 Cr | ₹1,211 Cr | ₹1,598 Cr | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Total Liabilities | ₹2,475 Cr | ₹7,410 Cr | ₹8,046 Cr | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Assets | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Fixed Assets | ₹701 Cr | ₹2,679 Cr | ₹2,980 Cr | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Investments | ₹630 Cr | ₹1,341 Cr | ₹1,525 Cr | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Receivables | — | — | — | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Inventory | — | — | — | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Cash & Equivalents | — | — | — | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Other Assets | ₹972 Cr | ₹2,576 Cr | ₹2,762 Cr | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Total Assets | ₹2,475 Cr | ₹7,410 Cr | ₹8,046 Cr | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Register free to see 8 more years.
| Period | Operating | Investing | Financing | Net Cash Flow |
|---|---|---|---|---|
| Mar 2016 | ₹83 Cr | ₹50 Cr | ₹-421 Cr | — |
| Mar 2017 | ₹73 Cr | ₹-2,205 Cr | ₹2,944 Cr | — |
| Mar 2018 | ₹288 Cr | ₹-1,222 Cr | ₹338 Cr | — |
| Mar 2019 | ||||
| Mar 2020 | ||||
| Mar 2021 | ||||
| Mar 2022 | ||||
| Mar 2023 | ||||
| Mar 2024 | ||||
| Mar 2025 | ||||
| Mar 2026 |
Register free to see 8 more years.
No dividend history available.
No corporate actions recorded.
| Company | M.Cap | P/E | ROE | 1Y Return |
|---|---|---|---|---|
| Sun Pharmaceutical Industries Ltd | ₹4,51,075 Cr | 41.3 | 0.00% | +7.16% |
| Dr Reddys Laboratories Ltd | ₹1,11,310 Cr | 19.7 | +11.84% | +8.69% |
| Cipla Ltd | ₹1,15,638 Cr | 25.5 | +11.74% | -2.61% |
| Apollo Hospitals Enterprise Ltd | ₹1,16,201 Cr | 64.5 | 0.00% | +24.63% |
| Divis Laboratories Ltd | ₹1,79,486 Cr | 72.5 | 0.00% | +7.59% |
Create a free account to see institutional ownership snapshots.
Create a free account to view recent director and promoter trades.
Create a free account to view recent institutional deal activity.
Create a free account to view analyst estimate summaries.
Create a free account to view ESG risk and governance summaries.
Upgrade to view issuer ratings, instruments, outlooks, and rating history.
rupiya.io is for research and education only. Metrics shown are not investment advice. Validate with SEBI-regulated disclosures before acting.